Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 50, Issue 24, Pages 5871-5874Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm0708578
Keywords
-
Categories
Ask authors/readers for more resources
A novel '' Keppler type '' ruthenium(III) compound trans[bis(2-amino 5-methylthiazole)tetrachlororuthenate(III)] 1, of potential interest as an anticancer agent, was designed, synthesized, and characterized. Its interactions with various proteins were analyzed, including the selenoenzyme thioredoxin reductase, an emerging target for anticancer metallodrugs. The selective inhibition of the cytosolic form of this selenoenzyme was documented, this being the first report of significant thioredoxin reductase inhibition by a ruthenium compound.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available